Please login to the form below

Xtandi

This page shows the latest Xtandi news and features for those working in and with pharma, biotech and healthcare.

Givlaari, Rybelsus lead crowded CHMP recommendations

Nubeqa will go head-to-head in the non-metastatic castration-resistant prostate cancer market with J&J’s Erleada (apalutamide), as well as Pfizer/Astellas’ Xtandi (enzalutamide).

Latest news

J&J gets EMA nod for wider use of Erleada in prostate cancer

Maintains a regulatory lead over rival Xtandi. Johnson &Johnson has clinched another approval for its prostate cancer drug Erleada in Europe, maintaining a regulatory lead over rival Xtandi from Astellas and ... Erleada can now be used for mCSPC patients
Clovis leapfrogs PARP rivals, filing Rubraca for prostate cancer

Johnson &Johnson’s Zytiga (abiraterone) or Pfizer’s Xtandi (enzalutamide).
Pfizer raises forecast following growth of biopharma business

Pfizer CEO Albert Bourla. Pfizer’s prostate cancer therapy Xtandi (enzalutamide) also grew in alliance revenues by 25% to $225m. ... For Pfizer, the potential approval in this indication could help drive Xtandi's growth even further – the drug picked
Lynparza scores another positive phase 3 prostate cancer study

Zytiga (abiraterone acetate) or Pfizer’s Xtandi (enzalutamide). ... The drug was compared to Xtandi or Zytiga in the second-line setting, and also focused on patients with HRRm gene mutations.
J&J puts pressure on rivals with new Erleada okay in prostate cancer

FDA previously granted priority review in this indication. Johnson &Johnson has bagged an FDA approval for Erleada in metastatic castration-sensitive prostate cancer (mCSPC), gaining an advantage over main rival Xtandi ... Androgen inhibitor Erleada

More from news
Approximately 30 fully matching, plus 42 partially matching documents found.

Latest Intelligence

Drug launches to watch in 2019

Analysts believe the drug could achieve peak sales of around $1.7bn, but will face fierce competition from the likes of Pfizer and Astellas’ established Xtandi. ... It also gives J&J a leg-up in what looks set to be a big market tussle with Pfizer and
Deal Watch August 2016

35! Although Pfizer pointed to the $2.2bn of Xtandi sales for advanced metastatic prostate cancer, this product has been under licence to Astellas since 2009, including a US profit share ... Headline £m. Medivation (US). Pfizer (US). Company acquisition.
Deal Watch May 2016

The prize of course is the one marketed product in Medivation's portfolio, Xtandi [enzalutamide for the treatment of advanced prostate cancer] with sales estimated to reach $1.5bn and already
Deal Watch March 2016

Only one other deal had an upfront value of more than $1bn: the sale by UCLA to Royalty Pharma of its royalty rights to Xtandi with a cash payment of ... Research collaboration. $2, 258. UCLA/ Royalty Pharma. Xtandi – androgen receptor inhibitor.
Astellas: Ten years young

Its efforts to date in oncology have seen it form a prostate cancer franchise on the back of Eligard (leuprolide acetate) and more recently Xtandi (enzalutamide). ... There it is currently conducting a series of investigations in breast cancer to assess

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest appointments

Dendreon appoints new R&D lead

Joining from Astellas Pharma, Dr Brown most recently served as senior medical director of oncology, where he led US medical strategy for the prostate cancer drug Xtandi (enzalutamide).
Astellas promotes John Demaree

Demaree was promoted from his position as executive director of oncology marketing, where he oversaw the launch of prostate cancer drug Xtandi (enzalutamide) and promotion of lung cancer therapy Tarceva (erlotinib).
Astellas makes senior EMEA appointments

Both men are veterans of Astellas. Dew joined the company in 2006 as senior manager business development and has worked on major products such as Xtandi.
Astellas poaches new oncology head from Takeda

She will now lead Astellas' efforts in cancer, which include prostate cancer drug Xtandi (enzalutamide) and Tarveca (erlotinib) – a lung cancer drug co-marketed by Roche.

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Publications director: Competitive salary and bonus scheme

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Experienced medical editor: Competitive salary and bonus scheme

Group Director of Medical Affairs and Scientific Strategy, Medic...: Substantial six figure package

Account Director, Healthcare Communications: Salary TBC

Account Manager: £Competitive Salary

Brand Manager - Medium Global Pharma Company: £Competitive Financial Package

Senior Medical Writer, MedComms Agency: Salary TBC

Account Director: £Competitive Salary

Digital Associate Director - Medcomms: £65000 - £80000 per annum

Account Manager (PR): Great Benefits

Senior Medical Writer or Lead Medical Writer: £Competitive Salary

Scientific Director: £60000 - £85000 per annum, Benefits: Bonus, pension, subsidised gym and much more

Account Director, Medical Education: Salary TBC

Account director: Competitive salary and bonus scheme

Senior External Communications Lead: £Competitive Salary

Subscribe to our email news alerts

PMHub

Add my company

infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

Novo Nordisk awakens its ‘Sleeping Beauty’: Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...
How will the Tories’ historic win shape the NHS?: Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore the impact of December’s General Election result on 2020 and beyond...
CSR 'Christmas Spirit' 2019: OPEN Health champions CSR over Christmas by giving back to the community and increasing our activities and efforts...